// App-Quantinova.ai

S290 : SUTIMLIMAB, A TARGETED COMPLEMENT C1S INHIBITOR, IMPROVES QUALITY OF LIFE (QOL) IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FROM THE RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 CADENZA STUDY

Researchers

Presenter

  • Alexander Rth

Principal Investigators

  • Catherine M. Broome

  • Wilma Barcellini

  • Bernd Jilma

  • Quentin A. Hill

  • David Cella

  • Tor Henrik Anderson Tvedt

  • Masaki Yamaguchi

  • Michelle Lee

  • Frank Shafer

  • Braydon Schaible

  • Xiaoyu Jiang

  • Parija Patel

  • Florence Joly

  • Ilene C. Weitz

Medical Centers

  • Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

  • Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United States

  • Sanofi, Chilly-Mazarin, France

  • Department of Clinical Pharmacology, Medical University of Vienna, Austria

  • Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany

  • Sanofi,Warsaw,Pologne

  • Jane Anne Nohl Division of Hematology, Department of Medicine,Keck School of Medicine of USC,Los Angeles, CA,United States

  • Sanofi, Cambridge, United States

  • Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway

  • IRCCS Ca Granda, Ospedale Maggiore Policlinico, Milano, Italy

  • Division of Hematology, MedStar Georgetown University Hospital,Washington DC,Vereinigte Staaten

Locations

  • Japan

  • United States

  • France

  • Austria

  • Germany

  • Poland

  • Norway

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Alpha-tubulin N-acetyltransferase 1

  • Complement Component 1, S Subcomponent

Drug/Treatment

  • Mofezolac

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT03347396

  • NCT03347422

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved